|
|
Blood, 1 June 2004, Vol. 103, No. 11, pp. 4028-4035.
Prepublished online as a Blood First Edition Paper on February 19, 2004; DOI 10.1182/blood-2003-11-3929.
 Previous Article | Table of Contents | Next Article 
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS
A single recombinant anti-RhD IgG prevents RhD immunization: association of RhD-positive red blood cell clearance rate with polymorphisms in the Fc RIIA and FcIIIA genes
Sylvia Miescher,
Martin O. Spycher,
Hanspeter Amstutz,
Masja de Haas,
Marion Kleijer,
Ulrich J. Kalus,
Hartmut Radtke,
Alphonse Hubsch,
Irmgard Andresen,
Roland M. Martin, and
Johann Bichler
From ZLB Bioplasma AG, Bern, Switzerland; the Institute of Immunology, Inselspital, Bern, Switzerland; Division CLB, Sanquin, Amsterdam, The Netherlands; and the Department of Transfusion Medicine, University Clinics Charité, Berlin, Germany.
A single recombinant immunoglobulin G1 (IgG1) anti-RhD antibody (MonoRho) was compared with a currently used polyclonal anti-RhD product (Rhophylac) in a phase 1 study for safety, efficacy of Rhesus D (RhD)–positive red blood cell (RBC) clearance, and prevention of RhD immunization in RhD-negative men challenged with 15 mL RhD-positive RBCs. Both the polyclonal product and recombinant anti-RhD effectively cleared RhD-positive RBCs after intravenous and intramuscular injection. The recombinant anti-RhD demonstrated a slower clearance rate compared with the polyclonal anti-RhD. There was no dose response, and there was considerable variation among subjects who received the same dose of recombinant anti-RhD. Interestingly, RhD-positive RBC clearance rates were strongly associated with Fc receptor IIA (FcRIIA) and FcIIIA but not with FcIIIB polymorphisms. Subjects homozygous for FcRIIA-131H or FcRIIIA-158V allotypes showed a faster clearance rate compared with both the heterozygote and the corresponding alternative homozygote allotypes. A similar but less marked trend was seen for the polyclonal anti-RhD. Despite the variation in clearance rates there was no evidence of anti-RhD alloantibodies in any of the subjects at +6 months after the RBC challenge.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Letter in Blood Online:
-
Dose-response relationship and pharmacogenetics of anti-RhD monoclonal antibodies
- David Ternant, Marc Ohresser, Cécile Thomas, Guillaume Cartron, Hervé Watier, Gilles Paintaud, Alphonse Hubsch, Martin Spycher, Johann Bichler, and Sylvia Miescher
Blood 2005 106: 1503-1505.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
M. Kjaersgaard, R. Aslam, M. Kim, E. R. Speck, J. Freedman, D. I. H. Stewart, E. J. Wiersma, and J. W. Semple
Epitope specificity and isotype of monoclonal anti-D antibodies dictate their ability to inhibit phagocytosis of opsonized platelets
Blood,
August 15, 2007;
110(4):
1359 - 1361.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. L. Armour, D. R. Parry-Jones, N. Beharry, J. R. Ballinger, R. Mushens, R. K. Williams, C. Beatty, S. Stanworth, P. Lloyd-Evans, M. Scott, et al.
Intravascular survival of red cells coated with a mutated human anti-D antibody engineered to lack destructive activity
Blood,
April 1, 2006;
107(7):
2619 - 2626.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Ternant, M. Ohresser, C. Thomas, G. Cartron, H. Watier, G. Paintaud, A. Hubsch, M. Spycher, J. Bichler, and S. Miescher
Dose-response relationship and pharmacogenetics of anti-RhD monoclonal antibodies
Blood,
August 15, 2005;
106(4):
1503 - 1505.
[Full Text]
[PDF]
|
|
|
| |
